Bristol-Myers Squibb's Sprycel May Increase Hypertension Risk, FDA Says
Published: Oct 12, 2011
Bristol-Myers Squibb Co. (BMY)’s leukemia drug Sprycel may increase the risk of a rare condition that causes high blood pressure in the lungs’ arteries, U.S. regulators said today. Health-care providers should evaluate patients for signs of underlying cardiopulmonary disease before starting Sprycel, chemically known as dasatinib, and during treatment. If abnormally high blood pressure known as pulmonary arterial hypertension is confirmed, patients should discontinue the medicine, according to the safety announcement from the Food and Drug Administration.